Clinical Trial Search

Primary: Exercise-Induced Bronchoconstriction (EIB) Severity — 19.84; 10.94 Percentage (%) — p=0.339

Primary: Spirometry and Specific Airway Conductance Measured by Body Plethysmography Before and After Exercise Challenge After Randomized Administration of Either Inhaled…

Primary: Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Postdose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)…

Primary: Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Post-dose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)…

Primary: Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Post-dose in Patients With Exercise-Induced Bronchoconstriction…

Primary: Maximum Percentage Fall From Baseline in Forced Expiratory Volume in 1 Second (FEV1) up to 60 Minutes After the Exercise Challenge — 6.21; 22.38 percentage change from…

Primary: Maximum Percentage Fall From Post-dose, Pre-exercise Baseline in Forced Expiratory Volume in 1 Second (FEV₁) Observed up to 60 Minutes Post-exercise Challenge — 5.45…

Primary: Measured Before and 30 Minutes After Exercise in Each 1 Day Condition — 6.98; 5.96; -1.38; -.35 litres

Primary: Maximal Percent Decrease in Forced Expiratory Volume in One Second (FEV1) Following Exercise Challenge at 12 Hours (Hrs) Post Evening Dose From Pre-exercise FEV1…

Primary: Maximal Percentage Change From Pre-exercise Baseline Forced Expiratory Volume in 1 Second (FEV1) to the Minimum FEV1 Collected Within 60 Minutes Following the Exercise…

Primary: Maximum Percentage Fall From Post-dose, Pre-exercise Baseline in Forced Expiratory Volume in 1 Second (FEV₁) Observed up to 60 Minutes Post-exercise Challenge — 6.95…

Primary: Maximum Post-exercise Percent (%) Fall in FEV1 — 10.57; 13.82 Percent change from baseline — p=0.009

Primary: Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 24 Hours — 0.793; 1.950; 2.504; 3.236 Log base 2…

Primary: Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP) at 8 Weeks — 60; 71; 84; 69 cmH2O — p=0.005

Primary: Change in Forced Expiratory Volume in 1 Second (FEV1) — -24.66; -8.44; -9.15; -16.17 Percentage drop in FEV1 — p=<0.0001

Primary: Airway Resistance at 5 Hz (R5) at Baseline (Pre-mepolizumab Initiation) — 0.51; 0.39; 0.43 kPa/L/s

Primary: Change in Exhaled Nitric Oxide From Baseline to Week 12 — -11.0 parts per billion (ppb) — p=0.005

Primary: Albuterol-induced Change in FEV1 — 0.27; 0.18; 0.32; 0.20 liters

Primary: The Percentage of Patients With Loss of Asthma Control — 17 Participants

Primary: Airway Blood Flow Response to Albuterol — 2.85; -1.43; 17.93; 4.03 μl/min/ml

Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L

Primary: Number of Participants With 1 or More Severe Asthma Exacerbations — 186; 154 participants — p=0.036

Primary: Airway Blood Flow — 2.13; 13.05 ΔQaw (ul/min/ml)

Primary: Albuterol Induced Change in Qaw Before and After Fluticasone or Placebo — 40.9; 0.0 % change

Primary: Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Postdose — 15.35; 20.00 Percent fall in FEV1 — p=0.020

Primary: Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks — -5.85; 0.61; -5.24 Percent change

Primary: The Percentage of Participants With Asthma Who Rated the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrated Correct Use of the Inhaler at the…

Primary: Maximum Change From Baseline in Airway Blood Flow (Qaw) — -11.0; 14.1; 23.9; 25.5 change from baseline ( µl/min/ml) — p=< 0.001

Primary: Adenosine Challenge Test — 18.46; 142.61 mg/ml

Primary: Number of Subjects With Serious Adverse Events — 0; 0 participants